

December 14, 2023

Dear Valued Partner,

At Johnson & Johnson, we believe health is everything. We are excited to share that we are uniting our diverse businesses under a refreshed Johnson & Johnson brand that reinforces our bold approach to innovation in healthcare.

Since 2010, our stakeholders have known us as the Janssen Pharmaceutical Companies of Johnson & Johnson. Now, we are excited to share that we will evolve our brand name/logo over time to Johnson & Johnson.

Johnson & Johnson has a long history of innovation, starting with our first pharmaceutical product in 1931. In 1961, Janssen joined many other healthcare legacies as part of the Johnson & Johnson Family of Companies. Our new brand is a significant opportunity to simplify the way we communicate who we are with the world.

This change will not impact our product offering, planned clinical trials or how we collaborate with you. We will continue to conduct our business in the same way. You will begin to see our new brand name/logo in our business communications. Over the next several years, we will update our company logo on product packaging and regulatory filings. The names of our prescription products will not change, nor will the names of the sponsoring organization on our Clinical Trial Agreements.

Although we are adopting a new brand identity, our purpose remains the same. At Johnson & Johnson Innovative Medicine, we innovate with purpose to lead where medicine is going. Patients will always inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the potential medicines of tomorrow. We invite you to visit our website: [Johnson & Johnson Marks New Era as Global Healthcare Company with Updated Visual Identity \(jnj.com\)](https://www.jnj.com) to learn more about our brand evolution.

As a valued partner, your relationship is important to us. If you have any questions, please feel free to contact me at [dhensle1@its.jnj.com](mailto:dhensle1@its.jnj.com) or 330.206.8141.

Thank you,



Daniella Hensley  
Senior Director, US GCO (Global Clinical Operations)  
J&J Innovative Medicine, Oncology